For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
|Videos|August 9, 2016
The Role of PARP Inhibitors in Prostate Cancer
Author(s)Christopher E. Barbieri, MD, PhD
Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the role of PARP inhibitors in castration-resistant prostate cancer.
Advertisement
Advertisement
Related to this article
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
2
FDA Panel Votes in Favor of Galleri Multi-Cancer Early Detection Test
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
4
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
5